245 related articles for article (PubMed ID: 35678235)
21. Reactive oxygen species in cancer stem cells of head and neck squamous cancer.
Qian X; Nie X; Yao W; Klinghammer K; Sudhoff H; Kaufmann AM; Albers AE
Semin Cancer Biol; 2018 Dec; 53():248-257. PubMed ID: 29935313
[TBL] [Abstract][Full Text] [Related]
22. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
23. Pluripotency transcription factor Nanog and its association with overall oral squamous cell carcinoma progression, cisplatin-resistance, invasion and stemness acquisition.
Kashyap T; Nath N; Mishra P; Jha A; Nagini S; Mishra R
Head Neck; 2020 Nov; 42(11):3282-3294. PubMed ID: 32710593
[TBL] [Abstract][Full Text] [Related]
24. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
Alam M; Mishra R
Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
[TBL] [Abstract][Full Text] [Related]
25. Cancer stem cell, cytokeratins and epithelial to mesenchymal transition markers expression in oral squamous cell carcinoma derived from ortothopic xenoimplantation of CD44
de Andrade NP; Rodrigues MF; Rodini CO; Nunes FD
Pathol Res Pract; 2017 Mar; 213(3):235-244. PubMed ID: 28214216
[TBL] [Abstract][Full Text] [Related]
26. Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
Naik PP; Mukhopadhyay S; Panda PK; Sinha N; Das CK; Mishra R; Patil S; Bhutia SK
Cell Prolif; 2018 Feb; 51(1):. PubMed ID: 29171106
[TBL] [Abstract][Full Text] [Related]
27. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Sakuma T; Uzawa K; Onda T; Shiiba M; Yokoe H; Shibahara T; Tanzawa H
Int J Oncol; 2006 Jul; 29(1):117-24. PubMed ID: 16773191
[TBL] [Abstract][Full Text] [Related]
28. Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells.
Han L; Li L; Wu G
Mol Cell Probes; 2022 Aug; 64():101821. PubMed ID: 35490795
[TBL] [Abstract][Full Text] [Related]
29. Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Wang TY; Peng CY; Lee SS; Chou MY; Yu CC; Chang YC
Oncotarget; 2016 Dec; 7(51):84072-84081. PubMed ID: 27557511
[TBL] [Abstract][Full Text] [Related]
30. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological blockade of HDAC6 attenuates cancer progression by inhibiting IL-1β and modulating immunosuppressive response in OSCC.
Mahale A; Routholla G; Lavanya S; Sharma P; Ghosh B; Kulkarni OP
Int Immunopharmacol; 2024 May; 132():111921. PubMed ID: 38547770
[TBL] [Abstract][Full Text] [Related]
32. DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
Martin CE; Nguyen A; Kang MK; Kim RH; Park NH; Shin KH
Exp Cell Res; 2021 Aug; 405(1):112656. PubMed ID: 34033760
[TBL] [Abstract][Full Text] [Related]
33. Thymoquinone potentiates anti-cancer effects of cisplatin in oral squamous cell carcinoma via targeting oxidative stress.
Fath MK; Nasiri K; Ghasemzadeh S; Nejati ST; Ghafari N; Masouleh SS; Dadgar E; Kazemi KS; Esfahaniani M
Chem Biol Drug Des; 2024 Mar; 103(3):e14492. PubMed ID: 38485457
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma.
Bourguignon LY; Wong G; Shiina M
J Biol Chem; 2016 May; 291(20):10571-85. PubMed ID: 27002147
[TBL] [Abstract][Full Text] [Related]
35. Entinostat is a novel therapeutic agent to treat oral squamous cell carcinoma.
Marques AEM; do Nascimento Filho CHV; Marinho Bezerra TM; Guerra ENS; Castilho RM; Squarize CH
J Oral Pathol Med; 2020 Sep; 49(8):771-779. PubMed ID: 32450006
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
37. Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Tao H; Chen YY; Sun ZW; Chen HL; Chen M
J Cell Biochem; 2018 Aug; 119(8):6623-6632. PubMed ID: 29665050
[TBL] [Abstract][Full Text] [Related]
38. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract][Full Text] [Related]
39. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
40. PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer.
Li P; Wang W; Zhu B; Wang Y; Li J; Wang C; Wang C; Li Q
Environ Toxicol; 2024 May; 39(5):2869-2880. PubMed ID: 38294069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
